Search results
Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial. Cannabis and/or cannabinoids may improve refractory, chemotherapy-induced nausea and vomiting when added to guideline-concordant antiemetic regimens.
13 mar 2024 · Adults with cancer using cannabis or cannabinoids should understand that the clinical evidence to support their use as cancer-directed therapy in humans is lacking.
13 mar 2024 · Cannabis and/or cannabinoids used as cancer-directed treatment may cause significant clinical (eg, fatigue, confusion, feeling high) and financial toxicities without good-quality evidence of clinical benefit.
27 mar 2023 · Objectives: Describe the pharmacodynamics of medical marijuana. Identify the active compounds within the cannabis plant that hold potential therapeutic benefits within the field of oncology. Outline the potential adverse events a patient may experience while consuming medical marijuana.
20 maj 2022 · The results of this study suggest that MC treatment is generally safe for oncology patients and can potentially reduce the burden of associated symptoms with no serious MC-related adverse effects. Keywords: medical use, cannabis, phytocannabinoids, oncology, cancer, prospective.
22 lut 2022 · We will assess cannabis‐based medicines (plant‐based cannabinoids (cannabidiol, dronabinol, nabiximols)), or synthetic cannabinoids (nabilone) or medical cannabis (cannabis flowers or full spectrum cannabis extracts) at any dose or by any route that were administered for the relief of cancer pain, if compared with placebo or other ...
6 mar 2023 · The MASCC panel recommends against the use of cannabinoids as an adjuvant analgesic for cancer pain and suggests that the potential risk of harm and adverse events be carefully considered for all cancer patients, particularly with treatment with a checkpoint inhibitor.
